Search

Your search keyword '"Bailey, Lynda"' showing total 7 results
Start Over Author "Bailey, Lynda"
7 results on '"Bailey, Lynda"'

1. P139 Rituximab in a large UK centre during the COVID-19 pandemic: the effects of employing a reduced dosing regimen on clinical response in Rheumatoid Arthritis patients

Author

McLorinan, Joanna, primary, Slade, Maria, additional, Leong, Chi-han, additional, Baker, Josie, additional, Bailey, Lynda, additional, Nam, Jacqueline, additional, Bissell, Lesley-Anne, additional, Emery, Paul, additional, Dass, Shouvik, additional, and Saleem, Benazir, additional

Published
2023
Full Text
View/download PDF

2. Real-world experience of effectiveness of non-medical switch from originator to biosimilar rituximab in rheumatoid arthritis

Author

Melville, Andrew R, Yusof, Md Yuzaiful Md, Fitton, John, Garcia-Montoya, Leticia, Bailey, Lynda, Dass, Shouvik, Emery, Paul, Buch, Maya, and Saleem , Benazir

Abstract

Objective: To evaluate the impact of non-medical switch from rituximab originator (RTX-O) to biosimilar (RTX-B) in patients with rheumatoid arthritis (RA).Methods: Between October 2017 and October 2019, all patients on RTX-O in our centre requiring re-treatment were switched to RTX-B unless declined by patient or specified by treating clinician. Switch strategy effectiveness was assessed retrospectively using DAS28-CRP(3) and RTX retention, with patients remaining on RTX-O as a comparator group.Results: 255/337 patients (75.6%) switched to RTX-B while 82 (24.3%) remained on RTX-O. There was no difference in DAS28-CRP(3) 4 months post-RTX-B switch versus same time-point post-RTX-O previous cycle (paired data available in 60%). Eighteen month retention estimates were 75.6% (95% CI 69.4–80.7) for RTX-B group and 82.3% (95% CI 70.4–89.8) for RTX-O [adjusted HR 1.52 (95% CI 0.85-2.73)]. 42/255 patients (16.5%) discontinued RTX-B for loss of effectiveness (LOE), 5 (2.0%) for AE. Risk of RTX-B discontinuation was associated with comorbidities and ≥2 previous bDMARDs. Risk of adverse outcome RTX cessation was associated with comorbidities, and reduced risk with number of previous RTX-O cycles and pre-switch cycle B-cell depletion. 34/255 patients (13.3%) switched back to RTX-O (LOE=30, AE=4), while 13/255 (5.1%) started other b/tsDMARDs. Of patients switched back for LOE, 28/30 remained on RTX-O at mean 7.7 months follow-up. Conclusion: Non-medical switch to RTX-B was largely effective. Factors associated with RTX-B discontinuation, including comorbidities, previous bDMARDs, and RTX-O treatment history, may inform switch decisions. Most patients switched back to RTX-O for LOE remained on treatment at short-term follow-up.

Published
2021
Full Text
View/download PDF

4. HURRICANE.

Author

Bailey, Lynda U.

Published
2022

5. Effect of Fatigue, Older Age, Higher Body Mass Index, and Female Sex on Disability in Early Rheumatoid Arthritis in the Treatment‐to‐Target Era

Author

Twigg, Sarah, Hensor, Elizabeth M. A., Freeston, Jane, Tan, Ai Lyn, Emery, Paul, Tennant, Alan, Morgan, Ann W., Conaghan, Philip, Keenan, Anne‐Maree, Hensor, Elizabeth, Quinn, Mark, Gough, Andrew, Green, Michael, Reece, Richard, Hordon, Lesley, Helliwell, Philip, Melsom, Richard, Doherty, Sheelagh, Adebajo, Ade, Harvey, Andrew, Jarrett, Steve, Huston, Gareth, Isdale, Amanda, Martin, Mike, Karim, Zunaid, McGonagle, Dennis, Pease, Colin, Cox, Sally, Bejarano, Victoria, Nam, Jackie, Villeneuve, Edith, Brown, Claire, Thomas, Christine, Pickles, David, Hammond, Alison, Neville, Beverley, Fairclough, Alan, Nunns, Caroline, Gill, Anne, Green, Julie, Rhys‐Evans, Belinda, Padwell, Barbara, Madden, Julie, Taylor, Lynda, Smith, Sally, King, Heather, Firth, Jill, Heard, Jayne, Sigsworth, Linda, Corscadden, Diane, Henshaw, Karen, Rashid, Lubna‐Haroon, Martin, Stephen, Robinson, James, Kozera, Lukasz, Burksa, Agata, Fahy, Sarah, Paterson, Andrea, Hensor, Elizabeth, Ponchel, Frederique, Buch, Maya, Nam, Jackie, Villeneuve, Edith, Conaghan, Philip, Andrews, Jacqueline, Wakefield, Richard, McGonagle, Denis, Marzo‐Ortega, Helena, Das, Sudipto, Horton, Sarah, Mackie, Sarah, Thomas, Rebecca, Bissell, Lesley Ann, Rakieh, Chadi, Ash, Zoe, Aslam, Amir, Saleem, Benazir, Coates, Laura, Fazal, Fahad, Hunt, Laura, Vital, Ed, Ferguson, Esme, Else, Sara, Tran, Gui, Zayat, Ahmed, Abignano, Guiseppina, Yousef, Yuz, Raghunath, Radhika, Mathieson, Hannah, Ramakumain, Chitra, Gul, Hanna, Mahmood, Mahwish, Fitzgerald, Pauline, Robinson, Matthew, Ward, Jason, Wells, Beverly, Pickles, David, Wordsworth, Oliver, Thomas, Christine, McManus, Alison, Bailey, Lynda, Gray, Linda, Fitzgerald, Pauline, Russell, Kate, Davies, Jayne, Corscadden, Diane, Henshaw, Karen, Rashid, Lubna‐Haroon, Martin, Stephen, Robinson, James, Kozera, Lukasz, Burksa, Agata, Mbara, Katie, Fahy, Sarah, Halsted‐Rastrick, Jill, Connoly‐Thompson, Ged, Thompson, Jonathan, Weatherill, Ian, Paterson, Andrea, Horton, Laura, Jackson, Alwyn, and Hodgson, Richard

Abstract

To compare disease activity and disability over 2 years in early rheumatoid arthritis (RA) before and after implementation of treat‐to‐target therapy and identify predictors of adverse outcome. The Yorkshire Early Arthritis Register (YEAR) recruited 725 patients with early RAbetween 2002 and 2009, treated with a step‐up approach. The Inflammatory Arthritis Continuum study (IACON) recruited cases between 2010 and 2014 and treated to target. A total of 384 IACONcases met 2010 American College of Rheumatology/European League Against Rheumatism criteria. Latent growth curves of change in Disease Activity Score in 28 joints (DAS28) and the Health Assessment Questionnaire (HAQ) were compared between YEARand IACON. Latent class growth analysis identified trajectories of change. Baseline predictors of trajectories were identified using logistic regression. The mean DAS28 over 2 years was lower in IACONthan in YEAR. Latent trajectories of HAQchange in YEARwere high stable (21% of cohort), moderate reducing (35%), and low reducing (44%). Only moderate reducing (66%) and low reducing (34%) were seen in IACON. In both cohorts, female sex and fatigue predicted adverse HAQtrajectories (high stable and moderate reducing). Odds ratios (ORs) for moderate reducing compared to low reducing for women were 2.58 (95% confidence interval [95% CI] 1.69, 4.49) in YEARand 5.81 (95% CI2.44, 14.29) in IACON. ORs per centimeter fatigue visual analog score were 1.13 (95% CI1.07, 1.20) in YEARand 1.16 (95% CI1.12, 1.20) in IACON. Treat‐to‐target therapy gave more favorable trajectories of change in DAS28 and HAQ, but adverse HAQtrajectory was more likely in women with greater fatigue, suggesting such patients would benefit from interventions to improve function as well as reduce inflammation.

Published
2018
Full Text
View/download PDF

7. READERS’ SHOWCASE.

Author

Rusinga, Nectar, Burn, Jonquil, Cusack, Cass, Wells, Merryl, Bailey, Lynda, and MacDonald, Christine

Published
2015

Catalog

Books, media, physical & digital resources
See catalog results